{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:15:42Z","timestamp":1773677742066,"version":"3.50.1"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005412","name":"Shahid Chamran University of Ahvaz","doi-asserted-by":"publisher","award":["98\/3\/05\/14909"],"award-info":[{"award-number":["98\/3\/05\/14909"]}],"id":[{"id":"10.13039\/501100005412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The current study intended to trigger the immune response to cancer cells by using antibodies conjugated with bacterial antigens. The protein membrane of the MCF7 cell line was extracted and specific antibodies against cell membrane antigens was produced in rabbits. The specific antibodies were purified using chromatography methods and linked to <jats:italic>E<\/jats:italic>. <jats:italic>coli<\/jats:italic> antigens or doxorubicin using Diethylenetriamine pentaacetate (DTPA) linker. After confirmation of the conjugation process using SDS-PAGE and ATR-FTIR methods, the MCF7 and HUVEC cells were treated with various concentrations of the prepared conjugated antibodies along with human serum. The toxicity of each treatment against MCF7 and HUVEC cells was evaluated using the MTT assay. Also, polylactic acid scaffolds that contain 10\u00d710<jats:sup>4<\/jats:sup> MCF7 cells were surgically placed in the peritoneal cavity of the rats. After treatment of each group, induction of the inflammatory responses was evaluated on stained histological sections of the scaffolds. The lowest cytotoxic doses of the antigen conjugated-antibody, doxorubicin-conjugated-antibody was 4 and 1 \u03bcg\/mL, respectively. Doxorubicin conjugated antibodies displayed greater toxicity on both MCF7 and HUVEC cells. The in vivo finding revealed that the inflammatory cells were significantly higher in treating animals with antigen conjugated-antibody. The current synthetic agent stimulated the serum toxicity and induced an inflammatory response to MCF7 cell lines. Targeting of the bacterial antigens on tumor sites by immune system elements, could limit the growth of the tumor cells.<\/jats:p>","DOI":"10.1371\/journal.pone.0275776","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T17:34:07Z","timestamp":1665164047000},"page":"e0275776","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Triggering of the immune response to MCF7 cell line using conjugated antibody with bacterial antigens: In-vitro and in-vivo study"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9510-3464","authenticated-orcid":true,"given":"Mohammad","family":"Khosravi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaveh","family":"Khazaeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"KhademiMoghadam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"pone.0275776.ref001","first-page":"149","article-title":"New approaches for the treatment of cancer","volume":"46","author":"RK Jain","year":"2001","journal-title":"Adv Drug Delivery Rev"},{"key":"pone.0275776.ref002","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/bcr2889","article-title":"Choosing the right cell line for breast cancer research","volume":"13","author":"DL Holliday","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"6","key":"pone.0275776.ref003","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.cell.2012.02.034","article-title":"Antibody-based immunotherapy of cancer","volume":"148","author":"LM Weiner","year":"2012","journal-title":"Cell"},{"issue":"2","key":"pone.0275776.ref004","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd3877","article-title":"Advances in targeting cell surface signaling molecules for immune modulation","volume":"12","author":"S Yao","year":"2013","journal-title":"Nat. Rev. Drug Discov"},{"issue":"20","key":"pone.0275776.ref005","doi-asserted-by":"crossref","first-page":"6406","DOI":"10.1158\/1078-0432.CCR-11-0483","article-title":"Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends","volume":"17","author":"M Steiner","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"3","key":"pone.0275776.ref006","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"CL Vogel","year":"2002","journal-title":"J. Clin Oncol"},{"issue":"9","key":"pone.0275776.ref007","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nbt1137","article-title":"Monoclonal antibody therapy of cancer","volume":"23","author":"GP Adams","year":"2005","journal-title":"Nat biotechnol"},{"key":"pone.0275776.ref008","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nbt0901-819","article-title":"Monoclonal antibodies in the clinic","volume":"19","author":"J.M. Reichert","year":"2001","journal-title":"Nat. Biotechnol"},{"issue":"7","key":"pone.0275776.ref009","doi-asserted-by":"crossref","first-page":"e40208","DOI":"10.1371\/journal.pone.0040208","article-title":"Antibody-antigen-adjuvant conjugates enable co-delivery of antigen and adjuvant to dendritic cells in cis but only have partial targeting specificity","volume":"7","author":"M Kreutz","year":"2012","journal-title":"Plos One"},{"key":"pone.0275776.ref010","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.actbio.2021.06.040","article-title":"Multifunctional antibody-conjugated coiled-coil protein nanoparticles for selective cell targeting","volume":"131","author":"M Gil-Garcia","year":"2021","journal-title":"Acta Biomater"},{"issue":"1","key":"pone.0275776.ref011","first-page":"15","article-title":"Antibody-drug conjugates: present and future. Taylor & Francis","volume":"6","author":"A Beck","year":"2014","journal-title":"InMAbs"},{"issue":"10","key":"pone.0275776.ref012","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1021\/bc800289a","article-title":"Novel peptide linkers for highly potent antibody\u2212 auristatin conjugate","volume":"19","author":"SO Doronina","year":"2008","journal-title":"Bioconjugate chem"},{"issue":"1","key":"pone.0275776.ref013","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/cbdd.12085","article-title":"Antibody\u2010drug conjugates for the treatment of cancer","volume":"81","author":"JA Flygare","year":"2013","journal-title":"Chem Biol Drug Des CHEM BIOL DRUG DES"},{"key":"pone.0275776.ref014","article-title":"A Review on drug delivery system for tumor therapy","volume":"12","author":"G Liu","year":"2021","journal-title":"Front. Pharmacol"},{"issue":"9","key":"pone.0275776.ref015","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/jcp.54.9.669","article-title":"Immune responses to tumor antigens: implications for antigen specific immunotherapy of cancer","volume":"54","author":"D Jager","year":"2001","journal-title":"J. Clin. Pathol"},{"key":"pone.0275776.ref016","first-page":"36","article-title":"Combination of immunotherapy with anaerobic bacteria for immunogene therapy of solid tumours","volume":"13","author":"J Xu","year":"2009","journal-title":"Gene Ther. Mol. Biol"},{"issue":"1","key":"pone.0275776.ref017","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1423-0127-17-21","article-title":"Bacteria in cancer therapy: a novel experimental strategy","volume":"17","author":"S Patyar","year":"2010","journal-title":"J. Biomed. Sci"},{"key":"pone.0275776.ref018","doi-asserted-by":"crossref","first-page":"e72704","DOI":"10.1371\/journal.pone.0072704","article-title":"Cell Surface-Specific N-Glycan Profiling in Breast Cancer","volume":"8","author":"X Liu","year":"2013","journal-title":"Plos One"},{"key":"pone.0275776.ref019","first-page":"14","article-title":"Practical Immunology, fourth ed","author":"FC Hay","year":"2002","journal-title":"Blackwell Publishing Company, Malden"},{"key":"pone.0275776.ref020","first-page":"237","article-title":"Cell sensitivity assays: the MTT assay. Cancer cell culture","author":"J Van Meerloo","year":"2011","journal-title":"Humana Press"},{"issue":"3","key":"pone.0275776.ref021","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s13337-020-00612-z","article-title":"Newcastle disease virus suppress glycolysis pathway and induce breast cancer cells death","volume":"31","author":"AG Al-Ziaydi","year":"2020","journal-title":"Virus dis"},{"key":"pone.0275776.ref022","doi-asserted-by":"crossref","first-page":"012009","DOI":"10.1088\/1742-6596\/1003\/1\/012009","article-title":"Pathological and immunological study on infection with Escherichia coli in ale balb\/c mice","volume":"1003","author":"IH Ali","year":"2018","journal-title":"J. Phys. Conf. Ser"},{"issue":"2","key":"pone.0275776.ref023","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1023\/A:1012259529167","article-title":"Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research","volume":"4","author":"D Bouis","year":"2001","journal-title":"Angiogenesis"},{"issue":"4","key":"pone.0275776.ref024","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s12272-011-0408-5","article-title":"Electrospray fabrication of doxorubicin-chitosan-tripolyphosphate nanoparticles for delivery of doxorubicin","volume":"34","author":"K Songsurang","year":"2011","journal-title":"Arch. Pharm. Res"},{"issue":"38","key":"pone.0275776.ref025","doi-asserted-by":"crossref","first-page":"9033","DOI":"10.1039\/C4CE01137F","article-title":"Supramolecular hydroxyapatite complexes as theranostic near-infrared luminescent drug carriers","volume":"16","author":"SP Victor","year":"2014","journal-title":"Cryst Eng Comm"},{"issue":"1","key":"pone.0275776.ref026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13065-021-00752-3","article-title":"Quantitative analysis of doxorubicin hydrochloride and arterolane maleate by mid IR spectroscopy using transmission and reflectance modes","volume":"15","author":"R Bansal","year":"2021","journal-title":"BMC chemistry"},{"issue":"4","key":"pone.0275776.ref027","first-page":"96","article-title":"Construction of anti omp immobilized nanoporous membrane based electrochemical biosensor for the detection of E. coli.","volume":"4","author":"M Mungali","year":"2015","journal-title":"Glob. j. multidiscip. res. stud"},{"issue":"12","key":"pone.0275776.ref028","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1002\/jps.24683","article-title":"Assessing the utility of circular dichroism and FTIR spectroscopy in monoclonal-antibody comparability studies","volume":"104","author":"JC Lin","year":"2015","journal-title":"J. Pharm. Sci"},{"issue":"1","key":"pone.0275776.ref029","first-page":"1","article-title":"Fabrication, characterization, and biological evaluation of anti-HER2 indocyanine green-doxorubicin-encapsulated PEG-b-PLGA copolymeric nanoparticles for targeted photochemotherapy of breast cancer cells","volume":"7","author":"YH Lee","year":"2017","journal-title":"Sci rep"},{"key":"pone.0275776.ref030","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","article-title":"Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells","volume":"4","author":"FO Nestle","year":"1998","journal-title":"Nat Med"},{"issue":"2","key":"pone.0275776.ref031","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd3365","article-title":"Advances in the assessment and control of the effector functions of therapeutic antibodies","volume":"10","author":"XR Jiang","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"pone.0275776.ref032","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jnci\/djh131","article-title":"Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer","volume":"96","author":"MD Pegram","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"pone.0275776.ref033","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1073\/pnas.0508123103","article-title":"Engineered antibody Fc variants with enhanced effector function","volume":"103","author":"GA Lazar","year":"2006","journal-title":"Proc. Natl. Acad. Sci"},{"issue":"9","key":"pone.0275776.ref034","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/j.1349-7006.2009.01222.x","article-title":"Engineered therapeutic antibodies with improved effector functions","volume":"100","author":"T Kubota","year":"2009","journal-title":"Cancer sci"},{"issue":"19","key":"pone.0275776.ref035","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","article-title":"Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia","volume":"68","author":"HM Horton","year":"2008","journal-title":"Cancer Res"},{"issue":"3","key":"pone.0275776.ref036","first-page":"768","article-title":"Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood, Am","volume":"100","author":"J Lundin","year":"2002","journal-title":"J. Hematol"},{"issue":"3","key":"pone.0275776.ref037","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.4049\/jimmunol.171.3.1581","article-title":"Complement activation determines the therapeutic activity of rituximab in vivo","volume":"171","author":"N Di Gaetano","year":"2003","journal-title":"The J Immunol"},{"key":"pone.0275776.ref038","article-title":"The beneficial effects of bacterial infections on host resistance to cancer: End result in 449 cases","author":"HC Nauts","year":"1980","journal-title":"Cancer research institute monograph no. 8, New York, USA 2nd edition"},{"key":"pone.0275776.ref039","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1538-7836.2005.01110.x","article-title":"Coley\u2019s toxin revisited: immunotherapy or plasminogen activator therapy of cancer? J","volume":"3","author":"LR Zacharski","year":"2005","journal-title":"Thromb. Haemost"},{"issue":"14","key":"pone.0275776.ref040","doi-asserted-by":"crossref","first-page":"5860","DOI":"10.1158\/0008-5472.CAN-08-4855","article-title":"High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action","volume":"69","author":"SH Kim","year":"2009","journal-title":"Cancer Res"},{"issue":"31","key":"pone.0275776.ref041","doi-asserted-by":"crossref","first-page":"12879","DOI":"10.1073\/pnas.0701959104","article-title":"Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth","volume":"104","author":"M Loeffler","year":"2007","journal-title":"Proc. Natl. Acad. Sci"},{"issue":"9","key":"pone.0275776.ref042","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1158\/0008-5472.CAN-04-3002","article-title":"Cancer Immunotherapy Based on Killing of Salmonella-Infected Tumor Cells","volume":"65","author":"F Avogadri","year":"2005","journal-title":"Cancer Res"},{"issue":"1","key":"pone.0275776.ref043","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4161\/auto.6.1.10325","article-title":"Bacillus calmette-guerin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy","volume":"6","author":"JM Yuk","year":"2010","journal-title":"Autophagy"},{"key":"pone.0275776.ref044","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","article-title":"An endotoxin-induced serum factor that causes necrosis of tumors","volume":"72","author":"EA Carswell","year":"1975","journal-title":"Proc. Natl. Acad. Sci"},{"issue":"2","key":"pone.0275776.ref045","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/toxsci\/kfi316","article-title":"Pharmacologic and toxicologic evaluation of C. novyi-NT spores","volume":"88","author":"LA Diaz","year":"2005","journal-title":"Toxicol Sci"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0275776","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T17:35:04Z","timestamp":1665164104000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0275776"}},"subtitle":[],"editor":[{"given":"Amitava","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":45,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0275776","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]}}}